StockNews.com started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a report issued on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Stock Down 15.7 %
PIRS opened at $13.60 on Friday. The firm’s fifty day simple moving average is $15.31 and its two-hundred day simple moving average is $14.97. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $22.32. The company has a market cap of $17.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.61.
Institutional Investors Weigh In On Pieris Pharmaceuticals
A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. purchased a new position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned about 1.21% of Pieris Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 40.11% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Further Reading
- Five stocks we like better than Pieris Pharmaceuticals
- Where Do I Find 52-Week Highs and Lows?
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Comparing and Trading High PE Ratio Stocks
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20210329132542&h=45&w=95&zc=2){kind=logo}